KEY DETAILS
A Minnesota bill would classify health data, including GLP-1 prescription records, as sensitive data with added privacy protections.
A new GLP-1-like drug, ASC35, is recruiting 84 people with obesity or overweight for a first-in-human safety trial in China.
Minnesota lawmakers are considering a bill that would give health data, including records tied to GLP-1 prescriptions, stronger legal protection as sensitive information. At the same time, a new obesity drug called ASC35 has begun its first human safety trial in China. Neither development changes what you can get today, but both point to where prescribing and data practices may be headed. If you take or are considering a GLP-1 medication, it is worth watching how your prescription information is handled and what new options may eventually reach the market.
Minnesota Senate File 2940 would amend the state's Data Privacy Act so that consumer health data, including prescription records for drugs like Ozempic, Wegovy, and Zepbound, is classified as sensitive data with additional legal safeguards. That reclassification matters because it raises the bar for who can access this information and under what conditions. Insurers and employers have shown growing interest in tracking who is prescribed GLP-1 drugs, since these medications carry significant cost implications for health plans and workplace benefit budgets. If the bill passes, Minnesota residents could see tighter limits on how their GLP-1 prescription history is shared or used outside of direct medical care. Other states may watch how this plays out before deciding whether to pursue similar protections of their own.
ASC35 is now recruiting 84 participants with obesity or overweight for a Phase 1 trial in China, where researchers will evaluate its safety, tolerability, and how the drug behaves in the body. This is the earliest stage of human testing, meaning the primary goal is to confirm the drug does not cause unacceptable harm and to understand basic dosing patterns, not to prove it works as a long-term treatment. Phase 1 trials like this one typically involve a small group of participants and take place before any larger studies test effectiveness. Because ASC35 is described as GLP-1-like, it may work through a similar biological pathway as existing approved medications, though the trial has not yet established how it compares to them. Reaching the market, if it gets there at all, would require several more years of testing beyond this first phase.
Taken together, these two developments show that GLP-1 access is being shaped on two different fronts at once. On one side, states are starting to decide how closely your prescription history can be tracked and shared. On the other, drug developers are testing whether new options will eventually join the current lineup of treatments. Neither change affects your care today, so there is no need to act on either one right now. If you want to stay informed, it may help to check in periodically on how your state handles health data privacy and to ask your prescriber about any new treatment options as they move through testing.
Originally published on GLP1Laws.
Every Sunday, the weekly newsletter pulls the full week together: the news from GLP-1 Nation, the access updates from GLP1Laws, the latest GLP-1 Studio podcast episodes, and what changed in the Cozy Butter community.